Antimicrobial proteins and peptides in early life: Ontogeny and translational opportunities

Frontiers in Immunology

Volumn 7, Issue AUG, 2016, Pages

  Battersby, Anna J ^a,b   Khara, Jasmeet ^a,c   Wright, Victoria J ^a   Levy, Ofer ^d,e   Kampmann, Beate ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Medical Research Council (MRC) Unit The Gambia   (Gambia)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

antimicrobial peptides; Immunity; Infant; Infection; Innate; Newborn; Peptide; Protein

Indexed keywords

BRILACIDIN; INDOLICIDIN; PEPTIDE; PROTEIN; PROTEIN S100B; TALACTOFERRIN;

ADAPTIVE IMMUNITY; ANTIMICROBIAL ACTIVITY; BACTERIAL FLORA; BLOODSTREAM INFECTION; CHORIOAMNIONITIS; DEGRANULATION; HUMAN; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; ONTOGENY; PNEUMONIA; RESPIRATORY TRACT INFECTION; REVIEW; TRANSLATIONAL RESEARCH; VERY LOW BIRTH WEIGHT;

EID: 84989328833     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00309     Document Type: Review

References (97)

1. Marchant A, Kollmann TR. Understanding the ontogeny of the immune system to promote immune-mediated health for life. Front Immunol (2015) 6:77. doi:10.3389/fimmu.2015.00077
2. Battersby AJ, Gibbons DL. The gut mucosal immune system in the neonatal period. Pediatr Allergy Immunol (2013) 24(5):414-21. doi:10.1111/pai.12079
3. WHO. Levels and Trends in Childhood Mortality. New York, USA: WHO, United Nations Children's Fund (2013)
4. Fehervari Z. Neonatal non-responsiveness. Nat Immunol (2015) 16:906. doi:10.1038/ni.3261
5. Dowling DJ, Levy O. Ontogeny of early life immunity. Trends Immunol (2014) 35:299-310. doi:10.1016/j.it.2014.04.007
6. Strunk T, Currie A, Richmond P, Simmer K, Burgner D. Innate immunity in human newborn infants: prematurity means more than immaturity. J Matern Fetal Neonatal Med (2011) 24:25-31. doi:10.3109/14767058.2010.482605
7. Wardlaw T, You D, Hug L, Amouzou A, Newby H. UNICEF report: enormous progress in child survival but greater focus on newborns urgently needed. Reprod Health (2014) 11:82. doi:10.1186/1742-4755-11-82
8. Bernuth von H, Picard C, Puel A, Casanova J-L. Experimental and natural infections in MyD88-and IRAK-4-deficient mice and humans. Eur J Immunol (2012) 42:3126-35. doi:10.1002/eji.201242683
9. Picard C, Casanova J-L, Puel A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IκBα deficiency. Clin Microbiol Rev (2011) 24:490-7. doi:10.1128/CMR.00001-11
10. Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol (2004) 75:39-48. doi:10.1189/jlb.0403147
11. Levy O. Antimicrobial proteins and peptides: anti-infective molecules of mammalian leukocytes. J Leukoc Biol (2004) 76:909-25. doi:10.1189/jlb.0604320
12. Frew L, Stock SJ. Antimicrobial peptides and pregnancy. Reproduction (2011) 141:725-35. doi:10.1530/REP-10-0537
13. Kai-Larsen Y, Gudmundsson GH, Agerberth B. A review of the innate immune defence of the human foetus and newborn, with the emphasis on antimicrobial peptides. Acta Paediatr (2014) 103:1000-8. doi:10.1111/apa.12700
14. Levy O. Antimicrobial proteins and peptides of blood: templates for novel antimicrobial agents. Blood (2000) 96:2664-72
15. Pana Z-D, Kougia V, Roilides E. Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients: an update. Expert Opin Pharmacother (2015) 16:693-710. doi:10.1517/14656566.2015.1013936
16. Strunk T, Doherty D, Richmond P, Simmer K, Charles A, Levy O, et al. Reduced levels of antimicrobial proteins and peptides in human cord blood plasma. Arch Dis Child Fetal Neonatal Ed (2009) 94:F230-1. doi:10.1136/adc.2008.143438
17. Misawa Y, Baba A, Ito S, Tanaka M, Shiohara M. Vitamin D(3) induces expression of human cathelicidin antimicrobial peptide 18 in newborns. Int J Hematol (2009) 90:561-70. doi:10.1007/s12185-009-0452-9
18. Murakami M, Dorschner RA, Stern LJ, Lin KH, Gallo RL. Expression and secretion of cathelicidin antimicrobial peptides in murine mammary glands and human milk. Pediatr Res (2005) 57:10-5. doi:10.1203/01.PDR.0000148068.32201.50
19. Trend S, Strunk T, Hibbert J, Kok CH, Zhang G, Doherty DA, et al. Antimicrobial protein and peptide concentrations and activity in human breast milk consumed by preterm infants at risk of late-onset neonatal sepsis. PLoS One (2015) 10:e0117038. doi:10.1371/journal.pone.0117038
20. Kai-Larsen Y, Bergsson G, Gudmundsson GH, Printz G, Jörnvall H, Marchini G, et al. Antimicrobial components of the neonatal gut affected upon colonization. Pediatr Res (2007) 61:530-6. doi:10.1203/pdr.0b013e318045be83
21. Schaller-Bals S, Schulze A, Bals R. Increased levels of antimicrobial peptides in tracheal aspirates of newborn infants during infection. Am J Respir Crit Care Med (2002) 165:992-5. doi:10.1164/ajrccm.165.7.200110-020
22. Marchini G, Lindow S, Brismar H, Ståbi B, Berggren V, Ulfgren A-K, et al. The newborn infant is protected by an innate antimicrobial barrier: peptide antibiotics are present in the skin and vernix caseosa. Br J Dermatol (2002) 147:1127-34. doi:10.1046/j.1365-2133.2002.05014.x
23. Dorschner RA, Lin KH, Murakami M, Gallo RL. Neonatal skin in mice and humans expresses increased levels of antimicrobial peptides: innate immunity during development of the adaptive response. Pediatr Res (2003) 53:566-72. doi:10.1203/01.PDR.0000057205.64451.B7
24. Yoshio H, Tollin M, Gudmundsson GH, Lagercrantz H, Jörnvall H, Marchini G, et al. Antimicrobial polypeptides of human vernix caseosa and amniotic fluid: implications for newborn innate defense. Pediatr Res (2003) 53:211-6. doi:10.1203/01.PDR.0000047471.47777.B0
25. Faust K, Göpel W, Moser K, Temole G, Bartels M, Wieg C, et al. Differential expression of antimicrobial polypeptides in cord blood samples of preterm and term infants. Acta Paediatr (2014) 103:e143-7. doi:10.1111/apa.12544
26. Akinbi HT, Narendran V, Pass AK, Markart P, Hoath SB. Host defense proteins in vernix caseosa and amniotic fluid. Am J Obstet Gynecol (2004) 191:2090-6. doi:10.1016/j.ajog.2004.05.002
27. Olbrich P, Pavón A, Rosso ML, Molinos A, de Felipe B, Sanchez B, et al. Association of human beta-defensin-2 serum levels and sepsis in preterm neonates*. Pediatr Crit Care Med (2013) 14:796-800. doi:10.1097/PCC.0b013e3182975e0f
28. Campeotto F, Baldassarre M, Laforgia N, Viallon V, Kalach N, Amati L, et al. Fecal expression of human β-defensin-2 following birth. Neonatology (2010) 98:365-9. doi:10.1159/000315872
29. Jenke ACW, Zilbauer M, Postberg J, Wirth S. Human β-defensin 2 expression in ELBW infants with severe necrotizing enterocolitis. Pediatr Res (2012) 72:513-20. doi:10.1038/pr.2012.110
30. Starner TD, Agerberth B, Gudmundsson GH, McCray PB. Expression and activity of beta-defensins and LL-37 in the developing human lung. J Immunol (2005) 174:1608-15. doi:10.4049/jimmunol.174.3.1608
31. Levy O, Martin S, Eichenwald E, Ganz T, Valore E, Carroll SF, et al. Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein. Pediatrics (1999) 104:1327-33. doi:10.1542/peds.104.6.1327
32. Nupponen I, Turunen R, Nevalainen T, Peuravuori H, Pohjavuori M, Repo H, et al. Extracellular release of bactericidal/permeability-increasing protein in newborn infants. Pediatr Res (2002) 51:670-4. doi:10.1203/00006450-200206000-00002
33. Nathe KE, Parad R, Van Marter LJ, Lund CA, Suter EE, Hernandez-diaz S, et al. Endotoxin-directed innate immunity in tracheal aspirates of mechanically ventilated human neonates. Pediatr Res (2009) 66:191-6. doi:10.1203/PDR.0b013e3181aa33d7
34. Walker VP, Akinbi HT, Meinzen-Derr J, Narendran V, Visscher M, Hoath SB. Host defense proteins on the surface of neonatal skin: implications for innate immunity. J Pediatr (2008) 152:777-81. doi:10.1016/j.jpeds.2007.11.030
35. Huttner KM, Bevins CL. Antimicrobial peptides as mediators of epithelial host defense. Pediatr Res (1999) 45:785-94. doi:10.1203/00006450-199906000-00001
36. Selsted ME. A pocket guide to explorations of the defensin field. Curr Pharm Des (2007) 13:3061-4. doi:10.2174/138161207782110363
37. Salzman NH, Ghosh D, Huttner KM, Paterson Y, Bevins CL. Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature (2003) 422:522-6. doi:10.1038/nature01520
38. Lehrer RI, Ganz T. Cathelicidins: a family of endogenous antimicrobial peptides. Curr Opin Hematol (2002) 9:18-22. doi:10.1097/00062752-200201000-00004
39. Bals R, Wilson JM. Cathelicidins-a family of multifunctional antimicrobial peptides. Cell Mol Life Sci (2003) 60:711-20. doi:10.1007/s00018-003-2186-9
40. Bellm L, Lehrer RI, Ganz T. Protegrins: new antibiotics of mammalian origin. Expert Opin Investig Drugs (2000) 9:1731-42. doi:10.1517/13543784.9.8.1731
41. Levy O, Sisson RB, Kenyon J, Eichenwald E, Macone AB, Goldmann D. Enhancement of neonatal innate defense: effects of adding an N-terminal recombinant fragment of bactericidal/permeability-increasing protein on growth and tumor necrosis factor-inducing activity of gram-negative bacteria tested in neonatal cord blood ex vivo. Infect Immun (2000) 68:5120-5. doi:10.1128/IAI.68.9.5120-5125.2000
42. Levin M, Quint PA, Goldstein B, Barton P, Bradley JS, Shemie SD, et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 meningococcal sepsis study group. Lancet (2000) 356:961-7. doi:10.1016/S0140-6736(00)02712-4
43. Pergialiotis V, Konstantopoulos P, Karampetsou N, Koutaki D, Gkioka E, Perrea DN, et al. Calprotectin levels in necrotizing enterocolitis: a systematic review of the literature. Inflamm Res (2016). doi:10.1007/s00011-016-0963-9
44. Baker EN, Baker HM. Molecular structure, binding properties and dynamics of lactoferrin. Cell Mol Life Sci (2005) 62:2531-9. doi:10.1007/s00018-005-5368-9
45. Vogel HJ. Lactoferrin, a bird's eye view. Biochem Cell Biol (2012) 90:233-44. doi:10.1139/o2012-016
46. Yang D, Biragyn A, Hoover DM, Lubkowski J, Oppenheim JJ. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol (2004) 22:181-215. doi:10.1146/annurev.immunol.22.012703.104603
47. Ganz T. The role of antimicrobial peptides in innate immunity. Integr Comp Biol (2003) 43:300-4. doi:10.1093/icb/43.2.300
48. Canny G, Levy O, Furuta GT, Narravula-Alipati S, Sisson RB, Serhan CN, et al. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A (2002) 99:3902-7. doi:10.1073/pnas.052533799
49. Xie Z, Feng J, Yang W, Xiang F, Yang F, Zhao Y, et al. Human α-defensins are immune-related Kv1.3 channel inhibitors: new support for their roles in adaptive immunity. FASEB J (2015) 29(10):4324-33. doi:10.1096/fj.15-274787
50. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science (2004) 303:1532-5. doi:10.1126/science.1092385
51. Chu H, Pazgier M, Jung G, Nuccio S-P, Castillo PA, de Jong MF, et al. Human α-defensin 6 promotes mucosal innate immunity through self-assembled peptide nanonets. Science (2012) 337:477-81. doi:10.1126/science.1218831
52. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N Engl J Med (2009) 360:439-43. doi:10.1056/NEJMp0804651
53. Flamm RK, Rhomberg PR, Simpson KM, Farrell DJ, Sader HS, Jones RN. In vitro spectrum of pexiganan activity when tested against pathogens from diabetic foot infections and with selected resistance mechanisms. Antimicrob Agents Chemother (2015) 59:1751-4. doi:10.1128/AAC.04773-14
54. Haug BE, Strøm MB, Svendsen JSM. The medicinal chemistry of short lactoferricin-based antibacterial peptides. Curr Med Chem (2007) 14:1-18. doi:10.2174/092986707779313435
55. Vincent JL, Marshall JC, Dellinger RP, Simonson SG, Guntupalli K, Levy MM, et al. Talactoferrin in severe sepsis: results from the phase II/III oral talactoferrin in severe sepsis trial. Crit Care Med (2015) 43:1832-8. doi:10.1097/CCM.0000000000001090
56. Fox JL. Antimicrobial peptides stage a comeback. Nat Biotechnol (2013) 31:379-82. doi:10.1038/nbt.2572
57. Conlon JM, Mechkarska M. Host-defense peptides with therapeutic potential from skin secretions of frogs from the family pipidae. Pharmaceuticals (Basel) (2014) 7:58-77. doi:10.3390/ph7010058
58. Blackburn RM, Verlander NQ, Heath PT, Muller-Pebody B. The changing antibiotic susceptibility of bloodstream infections in the first month of life: informing antibiotic policies for early-and late-onset neonatal sepsis. Epidemiol Infect (2014) 142:803-11. doi:10.1017/S0950268813001520
59. Nelson A, Hultenby K, Hell E, Riedel HM, Brismar H, Flock J-I, et al. Staphylococcus epidermidis isolated from newborn infants express pilus-like structures and are inhibited by the cathelicidin-derived antimicrobial peptide LL37. Pediatr Res (2009) 66:174-8. doi:10.1203/PDR.0b013e3181a9d80c
60. Rogan MP, Geraghty P, Greene CM, O'Neill SJ, Taggart CC, McElvaney NG. Antimicrobial proteins and polypeptides in pulmonary innate defence. Respir Res (2006) 7:29. doi:10.1186/1465-9921-7-29
61. Scharf S, Zahlten J, Szymanski K, Hippenstiel S, Suttorp N, N'Guessan PD. Streptococcus pneumoniae induces human β-defensin-2 and-3 in human lung epithelium. Exp Lung Res (2012) 38:100-10. doi:10.3109/01902148.2011.652802
62. Tang Z, Xu L, Shi B, Deng H, Lai X, Liu J, et al. Oral administration of synthetic porcine beta-defensin-2 improves growth performance and cecal microbial flora and down-regulates the expression of intestinal toll-like receptor-4 and inflammatory cytokines in weaned piglets challenged with enterotoxigenic Escherichia coli. Anim Sci J (2015). doi:10.1111/asj.12540
63. Salzman NH, Hung K, Haribhai D, Chu H, Karlsson-Sjöberg J, Amir E, et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol (2010) 11:76-83. doi:10.1038/ni.1825
64. Ménard S, Förster V, Lotz M, Gütle D, Duerr CU, Gallo RL, et al. Developmental switch of intestinal antimicrobial peptide expression. J Exp Med (2008) 205:183-93. doi:10.1084/jem.20071022
65. Salzman NH, Polin RA, Harris MC, Ruchelli E, Hebra A, Zirin-Butler S, et al. Enteric defensin expression in necrotizing enterocolitis. Pediatr Res (1998) 44:20-6. doi:10.1203/00006450-199807000-00003
66. Neu J, Walker WA. Necrotizing enterocolitis. N Engl J Med (2011) 364:255-64. doi:10.1056/NEJMra1005408
67. Salzman NH, Underwood MA, Bevins CL. Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa. Semin Immunol (2007) 19:70-83. doi:10.1016/j.smim.2007.04.002
68. Ronayne de Ferrer PA, Baroni A, Sambucetti ME, López NE, Ceriani Cernadas JM. Lactoferrin levels in term and preterm milk. J Am Coll Nutr (2000) 19:370-3. doi:10.1080/07315724.2000.10718933
69. Minami J, Odamaki T, Hashikura N, Abe F, Xiao JZ. Lysozyme in breast milk is a selection factor for bifidobacterial colonisation in the infant intestine. Benef Microbes (2015) 7(1):53-60. doi:10.3920/BM2015.0041
70. Baricelli J, Rocafull MA, Vázquez D, Bastidas B, Báez-Ramirez E, Thomas LE. β-defensin-2 in breast milk displays a broad antimicrobial activity against pathogenic bacteria. J Pediatr (Rio J) (2015) 91:36-43. doi:10.1016/j.jped.2014.05.006
71. Sherman MP. Lactoferrin and necrotizing enterocolitis. Clin Perinatol (2013) 40:79-91. doi:10.1016/j.clp.2012.12.006
72. Murata M, Wakabayashi H, Yamauchi K, Abe F. Identification of milk proteins enhancing the antimicrobial activity of lactoferrin and lactoferricin. J Dairy Sci (2013) 96:4891-8. doi:10.3168/jds.2013-6612
73. Froy O. Regulation of mammalian defensin expression by toll-like receptor-dependent and independent signalling pathways. Cell Microbiol (2005) 7:1387-97. doi:10.1111/j.1462-5822.2005.00590.x
74. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science (2006) 311:1770-3. doi:10.1126/science.1123933
75. Biron CA. More things in heaven and earth: defining innate and adaptive immunity. Nat Immunol (2010) 11:1080-2. doi:10.1038/ni1210-1080
76. Mandic Havelka A, Yektaei-Karin E, Hultenby K, Sørensen OE, Lundahl J, Berggren V, et al. Maternal plasma level of antimicrobial peptide LL37 is a major determinant factor of neonatal plasma LL37 level. Acta Paediatr (2010) 99:836-41. doi:10.1111/j.1651-2227.2010.01726.x
77. Singh VV, Chauhan SK, Rai R, Kumar A, Singh SM, Rai G. Decreased pattern recognition receptor signaling, interferon-signature, and bactericidal/permeability-increasing protein gene expression in cord blood of term low birth weight human newborns. PLoS One (2013) 8:e62845. doi:10.1371/journal.pone.0062845
78. Yost CC, Cody MJ, Harris ES, Thornton NL, McInturff AM, Martinez ML, et al. Impaired neutrophil extracellular trap (NET) formation: a novel innate immune deficiency of human neonates. Blood (2009) 113:6419-27. doi:10.1182/blood-2008-07-171629
79. Camacho-Gonzalez A, Spearman PW, Stoll BJ. Neonatal infectious diseases: evaluation of neonatal sepsis. Pediatr Clin North Am (2013) 60:367-89. doi:10.1016/j.pcl.2012.12.003
80. Vergnano S, Sharland M, Kazembe P, Mwansambo C, Heath PT. Neonatal sepsis: an international perspective. Arch Dis Child Fetal Neonatal Ed (2005) 90:F220-4. doi:10.1136/adc.2002.022863
81. Barbeiro DF, Barbeiro HV, Zampieri FG, César Machado MC, Torggler Filho F, Gomes Cunha DM, et al. Cathelicidin LL-37 bloodstream surveillance is down regulated during septic shock. Microbes Infect (2013) 15:342-6. doi:10.1016/j.micinf.2013.01.001
82. Guntupalli K, Dean N, Morris PE, Bandi V, Margolis B, Rivers E, et al. A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Crit Care Med (2013) 41:706-16. doi:10.1097/CCM.0b013e3182741551
83. Velden WJFMVD, van Iersel TMP, Blijlevens NMA, Donnelly JP. Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11). BMC Med (2009) 7:44. doi:10.1186/1741-7015-7-44
84. Manzoni P, Rinaldi M, Cattani S, Pugni L, Romeo MG, Messner H, et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA (2009) 302:1421-8. doi:10.1001/jama.2009.1403
85. Manzoni P, Stolfi I, Messner H, Cattani S, Laforgia N, Romeo MG, et al. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics (2012) 129:116-23. doi:10.1542/peds.2011-0279
86. Manzoni P, Meyer M, Stolfi I, Rinaldi M, Cattani S, Pugni L, et al. Bovine lactoferrin supplementation for prevention of necrotizing enterocolitis in very-low-birth-weight neonates: a randomized clinical trial. Early Hum Dev (2014) 90(Suppl 1):S60-5. doi:10.1016/S0378-3782(14)70020-9
87. Akin IM, Atasay B, Dogu F, Okulu E, Arsan S, Karatas HD, et al. Oral lactoferrin to prevent nosocomial sepsis and necrotizing enterocolitis of premature neonates and effect on T-regulatory cells. Am J Perinatol (2014) 31:1111-20. doi:10.1055/s-0034-1371704
88. Ochoa TJ, Zegarra J, Cam L, Llanos R, Pezo A, Cruz K, et al. Randomized controlled trial of lactoferrin for prevention of sepsis in peruvian neonates less than 2500 g. Pediatr Infect Dis J (2015) 34:571-6. doi:10.1097/INF.0000000000000593
89. Giroir BP, Scannon PJ, Levin M. Bactericidal/permeability-increasing protein-lessons learned from the phase III, randomized, clinical trial of rBPI21 for adjunctive treatment of children with severe meningococcemia. Crit Care Med (2001) 29:S130-5. doi:10.1097/00003246-200107001-00039
90. Guinan EC, Barbon CM, Kalish LA, Parmar K, Kutok J, Mancuso CJ, et al. Bactericidal/permeability-increasing protein (rBPI21) and fluoroquinolone mitigate radiation-induced bone marrow aplasia and death. Sci Transl Med (2011) 3:110ra118. doi:10.1126/scitranslmed.3003126
91. Evans SE, Tuvim MJ, Fox CJ, Sachdev N, Gibiansky L, Dickey BF. Inhaled innate immune ligands to prevent pneumonia. Br J Pharmacol (2011) 163:195-206. doi:10.1111/j.1476-5381.2011.01237.x
92. Perron GG, Zasloff M, Bell G. Experimental evolution of resistance to an antimicrobial peptide. Proc Biol Sci (2006) 273:251-6. doi:10.1098/rspb.2005.3301
93. Cantey JB, Milstone AM. Bloodstream infections: epidemiology and resistance. Clin Perinatol (2015) 42:1-16-vii. doi:10.1016/j.clp.2014.10.002
94. Desbois AP, Lang S, Gemmell CG, Coote PJ. Surface disinfection properties of the combination of an antimicrobial peptide, ranalexin, with an endopeptidase, lysostaphin, against methicillin-resistant Staphylococcus aureus (MRSA). J Appl Microbiol (2010) 108:723-30. doi:10.1111/j.1365-2672.2009.04472.x
95. Jindal HM, Le C-F, Mohd Yusof MY, Velayuthan RD, Lee VS, Zain SM, et al. Antimicrobial activity of novel synthetic peptides derived from indolicidin and ranalexin against Streptococcus pneumoniae. PLoS One (2015) 10:e0128532. doi:10.1371/journal.pone.0128532
96. Dosler S, Mataraci E. In vitro pharmacokinetics of antimicrobial cationic peptides alone and in combination with antibiotics against methicillin resistant Staphylococcus aureus biofilms. Peptides (2013) 49:53-8. doi:10.1016/j.peptides.2013.08.008
97. Le C-F, Yusof MYM, Hassan MAA, Lee VS, Isa DM, Sekaran SD. In vivo efficacy and molecular docking of designed peptide that exhibits potent antipneumococcal activity and synergises in combination with penicillin. Sci Rep (2015) 5:11886. doi:10.1038/srep11886